Comparative study between the new VIDAS EBV tests and Liason for the detection of Epstein-Barr virus VCA IgM, VCA/EA IgG and EBNA IgG antibodies in human serum samples
Abstract number: P561
Desmottes P., Foussadier A., Allard L.
Objectives: The VIDAS EBV reagents currently under development are aimed to detect immunoglobulins against Viral Capside Antigen (VCA), Early Antigen (EA) and Epstein-Barr nuclear antigen (EBNA). The aim of the study was to evaluate the results obtained by the 3 new automated VIDAS VCA IgM, VIDAS VCA/EA IgG and VIDAS EBNA IgG comparatively to the 4 corresponding tests available on LIAISON instrument (DiaSorin). Results concordance between techniques was determined for each kit, and a comparison of the methods was carried on acute EBV infection panels.
Methods: VIDAS EBV VCA/EA IgG and EBNA IgG reagents use specific EBV peptides coated on the solid phase to capture viral antigen immunoglobulins. The peptide-EBV IgG antibody complexes are later revealed using an anti-human IgG conjugated to Alkalin Phosphatase. VIDAS EBV VCA IgM is based on immunocapture of serum VCA IgM.
564 samples including 93 EBV primary infection (pi), 299 EBV past infection (PI) and 172 EBV negative serum (NS) were tested with both VIDAS and LIAISON VCA IgM kits.
338 samples including 45 EBV pi, 93 EBV PI and 200 EBV NS were tested with VIDAS VCA/EA IgG and compared to the combined results of LIAISON VCA and EA IgG kits.
483 samples including 64 EBV pi, 281 EBV PI and 138 EBV NS were tested with both VIDAS and LIAISON EBNA IgG kits.
The equivocal results of both methods were excluded for the concordance calculation.
Acute EBV infection panels:
149 samples from 24 acute EBV infection panels were tested with the 3 kits of each manufacturer.
Results: Concordance between VIDAS and LIAISON were found to be 95%, 97% and 99% for VCA IgM, VCA/EA IgG and EBNA IgG, respectively. Equivocal results rate was observed at 7.4% for LIAISON EBNA IgG, while VIDAS EBNA IgG yielded 2%, only.
Acute EBV infection panels testing showed:
better sensitivity for VIDAS VCA IgM compared to LIAISON VCA IgM.
VIDAS VCA/EA performed equally to LIAISON VCA and EA IgG,
odd reactivity of LIAISON EBNA IgG in early samples of 7 EBV panels out of 24.
Conclusions: The concordance between the new VIDAS EBV reagents and the corresponding LIAISON reagents was higher than 95%, but LIAISON EBNA IgG showed a significant rate of equivocal results. Comparison of the results of the 2 methods on acute EBV infection panels highlighted better performance for VIDAS VCA IgM and EBNA IgG than the respective LIAISON reagents.
|Session name:||19th European Congress of Clinical Microbiology and Infectious Diseases|
|Location:||Helsinki, Finland, 16 - 19 May 2009|
|Back to top|